Abstract 278P
Background
Burkitt Lymphoma (BL) is a rare and aggressive type of non-Hodgkin lymphoma (NHL), accounting for 0.8% of all B-cell lymphomas, with five-year survival ranging from 48% to 87%. Currently, intensive short-cycle and low-intensity multiagent immunochemotherapy regimens are used, however, it is not clear what health economic evidence exists for treatments in BL. Thereby, a systematic literature review (SLR) was conducted to understand the economic (costs and resource-use, economic evaluations) evidence base for patients with BL.
Methods
An SLR was conducted using Embase®, PubMed®, and EconLit from database inception through June 2019.
Results
A total of 758 abstracts and 132 full-texts were screened. We identified 2 economic evaluations and 7 studies reporting data for costs or resource-use covering four countries (Malawi, Nigeria, Uganda, Netherlands). The economic evidence varied in different regions due to unbalanced socio-economic development. The median length of hospital stay ranged from 13 days in Nigeria to 134 days in the Netherlands. The patients were also reluctant to healthcare and took 4-8 weeks from the onset of symptoms to present at the treatment centers in Nigeria. The total direct cost of treating BL was US$103.8 (Nigeria), US$350.14 (Uganda), and US$7342.17 (Netherlands) per patient. Dominant drivers for cost were the length of in-hospital stay and medication costs. Both the economic evaluations presented models for paediatric patients with no treatment as the comparator of choice and a continuous discount rate of 3%. Models were built from a governmental perspective with discounting and duration of treatment significantly impacting the sensitivity analysis. The cost per DALY averted was US$97 in Uganda and US$14,243 in Malawi, reflecting very cost-effective chemotherapeutic interventions.
Conclusions
This review highlights the limited literature on the economic dimensions of BL treatment, however, also demonstrates cost-effective interventions in resource-limited settings. There remains a need for future research and careful consideration of BL as an investment in health systems strengthening and improving the health outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
358P - Evaluation of continuous low dose versus standard dose capecitabine monotherapy as second/third-line chemotherapy for metastatic malignancies
Presenter: Swaroop Revannasiddaiah
Session: Poster display session
Resources:
Abstract
359P - Factors associated with economic burden among cancer patients with minor children: A cross-sectional web-based survey of an online cancer community
Presenter: Midori Yuki
Session: Poster display session
Resources:
Abstract
360P - Factors influencing treatment decisions among breast cancer patients in the Philippine general hospital cancer institute: Medical oncology outpatient clinic
Presenter: Bobby De Guzman
Session: Poster display session
Resources:
Abstract
361P - The role of volunteers in quality palliative care delivery
Presenter: NABANITA MANDAL
Session: Poster display session
Resources:
Abstract
362P - Survey to assess the efficacy of continuity of care delivered through an out of hours telephonic consultation liaison
Presenter: Rahul D. Arora
Session: Poster display session
Resources:
Abstract
366P - Activity of larotrectinib in TRK fusion cancer patients with primary central nervous system tumours
Presenter: David Ziegler
Session: Poster display session
Resources:
Abstract
367P - Molecular characteristics and efficacy of crizotinib among different subsets of MET Amplification detected by next-generation sequencing in lung cancer
Presenter: Jing Li
Session: Poster display session
Resources:
Abstract
368P - Genomic analysis of malaysian breast cancers unravel molecular differences from Caucasian breast cancers
Presenter: Soo-Hwang Teo
Session: Poster display session
Resources:
Abstract
369P - Institutional-based prospective molecular profiling of advanced solid tumours in Hong Kong: A report of 253 cases
Presenter: Herbert Loong
Session: Poster display session
Resources:
Abstract
370P - Tumour mutation burden analysis in a 5660-cancer-patient cohort reveals cancer type-specific mechanisms for high mutation burden
Presenter: Yuan-Sheng Zang
Session: Poster display session
Resources:
Abstract